

## **REMARKS/ARGUMENTS**

### **I. STATUS**

#### **A. SPECIFICATION**

The specification was amended to correct typographical errors. The amendments do not introduce new matter. Entry of these amendments is respectfully requested.

#### **B. CLAIMS**

Claims 41, 42, 50 and 54 - 69 are pending.

Claims 14, 15, 17 - 27, 43, 45, 46, 49 and 51 were cancelled herein. Cancellation of subject matter is without prejudice to subsequent revival for prosecution in a divisional or continuation application.

### **II. ALLOWABLE SUBJECT MATTER**

Applicants would like to thank the Examiner again for thoroughly reviewing the art and determining the allowable subject matter.

### **III. REJECTIONS UNDER 35 U.S.C. § 103(a)**

#### **A. CHAN, ROY OR YU IN VIEW OF HEEGAARD OR YU**

Claims 14, 17 - 21, 23, 26, 27 and 43, 45, 46, 49 and 51 were rejected under 35 U.S.C. § 103(a) as being unpatentable over Chan, Roy (Biochemistry 1998, 37, 4125 - 4136, hereinafter "Roy") or Yu in view of Heegaard or Yu. Applicants cancelled claims 14, 17 - 21, 23, 26, 27, 43, 45, 46, 49 and 51 herein, rendering the rejection moot.

#### **B. CHAN, ROY OR YU-B IN VIEW OF HEEGAARD OR YU-A AND FURTHER IN VIEW OF BOETTGER OR GOBOM**

Claim 15 was rejected under 35 U.S.C. § 103(a) as being unpatentable over Chan, Roy or Yu-B in view of Heegaard or Yu-A as applied to claim 14 above, and further in view of Boettger or Gobom. Claim 15 was cancelled herein, rendering the rejection moot.

#### **C. CHAN, ROY OR YU-B IN VIEW OF HEEGAARD OR YU-A AND FURTHER IN VIEW OF**

**BORNHORST.**

Claims 22 and 24 - 25 were rejected under 35 U.S.C. § 103(a) as unpatentable over Chan, Roy or Yu-B in view of Heegaard or Yu-A as applied to claims 19 - 20 above, and further in view of Bornhorst. Claims 22, 24 and 25 were cancelled herein, rendering the rejection moot.

**CONCLUSION**

Entry of this Amendment is respectfully requested. In view of the foregoing, Applicants believe all claims now pending in this application are in condition for allowance and the issuance of a formal Notice of Allowance is earnestly solicited.

Applicants believe that no fee is required for submission of this paper. In the event that an extension of time is required, the Commissioner is requested to grant that extension of time, which is required to make this response timely. The Commissioner is hereby authorized to charge any fee for such an extension of time or credit any overpayment for an extension of time to Deposit Account No. 50-2852.

If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (408)267-7214.

**Correspondence address**

Phynexus, Inc.  
IP Dept.  
3670 Charter Park Drive, Suite A  
San Jose, CA 95136  
[skalman@phynexus.com](mailto:skalman@phynexus.com)  
(408)267-7214 phone  
(408)267-7346 FAX

Respectfully submitted,

/Sue S. Kalman/

Sue S. Kalman  
Reg. No. 54,727